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RESUMO
Introdução: O objectivo geral deste artigo consiste em comparar o desempenho do EQ-5D e do SF-6D em quatro grupos de doentes 
que sofrem de asma, doença pulmonar obstrutiva crónica, cataratas e artrite reumatóide. Em particular, este artigo tem dois objectivos 
específicos: 1) estudar o nível de concordância entre os índices e os sistemas descritivos das dimensões do SF-6D e EQ-5D, e 2) 
analisar a capacidade de discriminação dos instrumentos.
Material e Métodos: Uma amostra de 643 doentes respondeu ao SF-36v2 e ao EQ-5D. Foram analisados a capacidade de discrimi-
nação dos instrumentos, bem como o nível de concordância entre os índices e os sistemas descritivos das dimensões do SF-6D e 
EQ-5D. O nível de concordância entre os instrumentos foi estudado com base em coeficientes de correlação e nos gráficos de Bland-
Altman, enquanto a influência da condição médica e de outras variáveis de natureza sociodemográfica nos índices foi analisada com 
o recurso a testes não paramétricos. Utilizaram-se também testes para amostras emparelhadas para identificar diferenças entre os 
scores finais dos instrumentos. 
Resultados e Discussão: Verificou-se a existência de uma correlação forte e de uma concordância elevada entre os dois índices. Em 
termos globais, os índices diferem por condição médica e por grupo sociodemográfico e ambos os instrumentos demonstraram uma 
capacidade discriminativa semelhante entre grupos sociodemográficos
Conclusão: Confirmou-se a hipótese de que o SF-6D gera valores de utilidade superiores em populações com doenças. O SF-6D 
e o EQ-5D parecem comportar-se de forma diferente em cada uma das doenças analisadas, uma vez que as medidas descritivas 
diferem entre instrumentos e os coeficientes de correlação não são uniformes. Os resultados demonstraram que o EQ-5D e o SF-6D 
geram valores de utilidade diferentes, mas que existe uma concordância elevada entre os dois instrumentos. Pode-se concluir que os 
resultados dos instrumentos não são directamente comparáveis.
Palavras-chave: Questionários; Qualidade de Vida; Indicadores Básicos de Saúde; Portugal.
ABSTRACT
Introduction: This research aims to explore the performance of the SF-6D and the EQ-5D in patients suffering from asthma, chronic 
obstructive pulmonary disease, cataracts, and rheumatoid arthritis. In particular, the aim of this research is twofold: 1) to study the level 
of agreement between the indexes and the descriptive systems of the dimensions of the SF-6D and the EQ-5D, and 2) to analyze the 
discriminative ability of the instruments.
Material and Methods: A sample of 643 patients completed both the SF-36v2 and the EQ-5D. The discriminative ability of the instru-
ments was analyzed. Furthermore, the level of agreement between the indexes and the descriptive systems of the dimensions of 
the SF-6D and the EQ-5D were studied. The level of agreement between instruments was investigated using correlation coefficients 
and the Bland-Altman plots, while the influence of medical condition and other socio-demographic variables was analyzed using non-
parametric tests. Paired-samples tests were used to identify differences between the scores. 
Results and Discussion: The results show a strong correlation and agreement between both indexes. Overall, questionnaire indexes 
differ by medical condition and socio-demographic groups and both instruments are able to discriminate between socio-demographic 
groups. 
Conclusion: This study confirmed the hypothesis that the SF-6D generates higher utility values in less healthy individuals. The SF-6D 
and the EQ-5D seem to perform differently in each of the diseases studied since the descriptive statistics differ between instruments 
and the level of correlation is not uniform. Results show that the instruments generate different utility values, but there is a strong 
agreement between both indexes. Thus, the two instruments are not interchangeable and their results cannot be directly comparable. 
Keywords: Health Status Indicators; Quality of Life; Questionnaires; Portugal.
INTRODUCTION
 The use of preference-based instruments for measuring 
health-related quality of life, such as the EQ-5D, the SF-
6D or the Health Utility Index in cost-utility analyses has 
been increasing over the past years. These instruments 
are indirect methods of valuation in health, which allow the 
measurement of utilities and which can be used to generate 
Quality Adjusted Life Years. They are an alternative to direct 
methods of valuation in health, such as the standard gamble 
and the time trade-off, which are complex, lengthy, and 
whose implementation is costly. In this regard, the use of the 
above-mentioned instruments, which are of quick and easy 
application, has intensified worldwide. These instruments 
are being applied to almost all kinds of diseases, including 
rheumatoid arthritis (RA),1 diabetes,2,3 asthma,4 stroke,5 
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AIDS,6 psychiatric illnesses,7 chronic obstructive pulmonary 
disease (COPD),8 multiple sclerosis,9 osteoporosis,10 
cancer,11,12 cataracts,13 among others. There has also been 
an increase in their use in measuring health-related quality 
of life (HRQoL) in national14-18 or regional19 populations as 
well as other sub-populations of interest.
 The EQ-5D is a measure of health status developed 
by the EuroQol Group in order to provide a simple, generic 
measure of health for clinical and economic appraisal. 
The EQ-5D is an instrument that comprises a descriptive 
system, wherein each one of its five dimensions has three 
levels, thus defining a total of 243 health states, and a visual 
analogue scale (VAS).20 Respondents rate their own health 
by choosing an option from each of the dimensions. The 
VAS is designed to look like a vertical thermometer whose 
scale is from 0 (worst imaginable health state) to 100 (best 
imaginable health state). The respondents indicate which 
value they would assign to their health state at that moment 
in time.20 A sample of 3 395 individuals, representative of the 
UK population, valued 42 health states through time trade-
off. Then econometric models were estimated to calculate 
unique preference values (utilities) for all health states.21 
These values, which constitute the EQ-5D utility index, vary 
between -0.59 and 1.00.21 The EQ-5D is the most popular 
preference-based instrument worldwide, with the largest 
number of translations (up until February 2013, it had been 
translated and validated for 102 different languages, with 
a further 67 at the stage of being officially ratified by the 
EuroQol Group). It is also the instrument that has the largest 
number of specific weighting systems, which allow the 
assigning of values to each health state described by the 
questionnaire. By mid-2012 there were weighting systems 
for at least 18 countries, although none was available for 
Portugal at that time (the Portuguese EQ-5D value set was 
published in 2013).22 Recently, a new version of the EQ-
5D has been developed, with five levels in each of the five 
dimensions, thus generating 3 125 different health states.23 
In February 2013, there were already 97 official translations 
for this version.
 The SF-6D is an econometric preference-based index 
which results from the conversion of 11 items from the SF-
36 into a classification system with six dimensions, each 
with four to six levels, allowing the generation of a total 
of 18,000 different health states.24 It was developed with 
the aim of allowing one of the mostly widely used health 
profiles in the world - the SF-36 - to be used in valuations; in 
other words, to allow a utility to be calculated. The authors 
used a representative sample of 611 individuals of the 
UK population who assigned values to 249 health states 
defined by the SF-6D, through the standard gamble.24 
These values permitted the estimation of econometric 
models, from which weights were assigned to the different 
levels of the SF-6D dimensions, thus generating values for 
all health states defined by the SF-6D. These health states 
values constitute an index – the SF-6D index - which can 
be seen as a continuous value ranging from 0.35 to 1.00.24 
At a later date, an SF-6D index derived from the SF-12 
was also established,24 although the former is still more 
widely used. There are now specific weighting systems for 
the UK, Portugal,26 Japan,27 Hong-Kong,28 Spain,29 Brazil30 
and Australia,31 with a value system for Singapore currently 
being determined.
 Since the number of preference-based instruments 
has been growing in recent years, and some comparative 
studies have identified non negligible discrepancies 
between different instruments, the importance of comparing 
the performance of the different instruments in specific 
patient populations has also been recognised in order to 
facilitate health professionals’ and researchers’ choices as 
to which instrument to use in their studies. At first glance, 
one might think that this choice would not be particularly 
important, as long as the instrument was based on 
preferences and, therefore, measured utilities. However, 
although these instruments all have these characteristics, 
many researchers have detected discrepancies in the utility 
values obtained by different instruments, mainly due to 
differences of the descriptive part of the measure. Indeed, 
an analysis of some of the studies published in recent years 
in the area of health economics and the measurement 
of HRQoL,32-48 including studies with a wide diversity of 
populations and interventions, shows only a weak or 
moderate level of agreement between different preference-
based instruments.
 In particular, the differences observed between the 
values generated by the EQ-5D and by the SF-6D have 
recently become the focus of attention. Several studies 
have been published with comparisons between these two 
instruments.33,49,50 However, most studies have been aimed at 
comparing and analysing the performance of the instruments 
in the context of a specific disease,36,38,40-44,46,48,51-57 or among 
specific groups of people.32,37,39 Few studies have been 
devoted to the comparison of the EQ-5D and the SF-6D in 
the general population,45,58 along with the comparison of their 
performances for more than one disease.35,59 The pattern of 
findings of most of these studies is that the EQ-5D tends 
to generate higher utility values than the SF-6D in groups 
with better states of health, whilst the opposite usually 
occurs in groups with worse health states. Furthermore, the 
conclusions of these studies have indicated a ceiling effect 
in the EQ-5D and a floor effect in the SF-6D, especially in 
patients with more serious illnesses.
 This paper aims to make a further contribution to the 
study of this problem, by comparing and analysing the 
performance of the three-level EQ-5D and the SF-6D 
(derived from the SF-36) across four patient groups. The 
groups were defined by respiratory diseases (namely, 
asthma and COPD), ophthalmological disorders (cataracts) 
and rheumatologic illnesses (RA).
MATERIAL AND METHODS
Sample
 The total sample used for the study consists of 643 
individuals, 115 of whom suffer from asthma, 72 from COPD, 
352 from cataracts and 104 from RA. A brief description of 
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each sub-sample, as well as the form and time period of 
data collection follows.
 Asthma - Between June 2005 and November 2006, 
asthmatic patients were recruited at Faro Central Hospital 
by pneumologists who agreed to collaborate in the study 
(which had been previously approved by the Health Ethics 
Committee of the Hospital).4 The inclusion criteria for 
recruitment were patients with a diagnosis of asthma who 
had given their informed consent. The individuals answered 
the Portuguese versions of the SF-36 v2 and the three-level 
EQ-5D, always following this order.
 COPD - Between October 2005 and November 2006, 
a group of pneumologists in Faro Central Hospital also 
recruited a sample of sequential patients diagnosed with 
COPD, who gave their informed consent to participate in 
the study. The selection was based on their willingness to 
participate in the study. The patients were asked to complete 
the Portuguese versions of the SF-36 v2 and the three-level 
EQ-5D, by this order.
 Cataracts - Between April 2005 and September 
2006,13,36 patients with cataracts on a waiting list to undergo 
surgery were selected in two hospitals in the Algarve, 
Patients who agreed to participate in the study, which had 
been previously approved by the Ethics Committees of 
the hospitals concerned, gave their informed consent and 
then completed the Portuguese versions of the SF-36 v2 
and the three-level EQ-5D. Individuals who were not able 
to see the words of the questionnaires were helped by a 
nurse, as well as illiterate patients. The order of application 
of the questionnaires was maintained throughout the study. 
Data were also collected to characterize the individuals. 
The questionnaires were administered immediately before 
surgery.
 Rheumatoid arthritis - Patients with RA who participated 
in the study either belonged to the Portuguese League 
Against Rheumatic Diseases or were patients referred by 
rheumatologists who agreed to cooperate in the study.1 The 
Portuguese versions of the SF-36 v2 and the three-level 
EQ-5D were applied to a sample of 104 patients diagnosed 
with RA. This order of the application of the questionnaires 
was maintained throughout the study. Data relating to the 
profile of the individual respondents were also collected. 
The data collection took place between December 2005 
and April 2006.
Data Analysis
 For the characterization of the samples, descriptive 
analyses were carried out by calculating empirical 
frequency distributions and descriptive statistics for the 
socio-demographic variables.
 Both the EQ-5D and the SF-6D indexes were calculated 
using the UK value sets,21,25 since although there is an SF-
6D value set for Portugal,26 there was no EQ-5D value set 
when the study was carried out.
 The utilities generated by the two instruments were 
globally analysed by medical condition and by socio-
demographic group, in order to identify their discriminative 
capabilities. The socio-demographic variables of gender, 
age and educational qualifications were used, as it has often 
been concluded that these variables show differences in 
terms of health. To this end, non-parametric tests were used 
since distributions of the SF-6D and the EQ-5D indexes are 
skewed. However, it was verified that similar results and the 
same conclusions were obtained if parametric tests were 
used. 
 The aim of the analysis of the indexes generated by 
the instruments was also to identify the existence of ceiling 
and floor effects among the instruments (i.e. large numbers 
of individuals reporting, respectively, the highest and the 
lowest possible values). In line with others,32 it was sought 
to assess the level of agreement between the instruments 
using correlation coefficients between the indexes (the 
Pearson’s r and the intraclass) and by similar dimension 
(the Spearman’s rho). The intraclass correlation coefficient 
(ICC) was based on a two-way mixed model with absolute 
agreement, and it was considered that a correlation greater 
than 0.5 would denote that the two indexes were strong 
correlated.60 Additionally, it was also produced the Bland-
Altman plots61 for the SF-6D and the EQ-5D by medical 
condition. The difference between the SF-6D and the 
EQ-5D indexes (y-axis) was plotted against the average 
value of the two indexes (x-axis), where the difference 
was calculated by subtracting the EQ-5D from the SF-6D 
index. Thus a point below (above) the x-axis denotes that 
a particular individual had a utility score that was higher 
(lower) according to the EQ-5D. Since the cluster of points 
should be around the x-axis, it was calculated the 95% limits 
of agreement [mean of differences ± 2 (standard deviation 
of differences)] and the percentage of points beyond these 
limits.
 The data analysis was performed using the IBM SPSS 
Statistics (version 20) and the Stata (version 9.1) software 
programmes. Differences were considered statistically 
significant at levels of significance of 5% and 1%.
RESULTS AND DISCUSSION
 Table 1 summarizes the main characteristics of the 
sample, both overall and by medical condition.
 Overall, the asthma and the RA sub-samples consisted 
mainly of fifty-year-old women, individuals who were 
married or living with a partner and residents in urban or 
semi-urban areas. The asthma sub-sample had a low 
level of educational qualifications, and consisted mainly 
of employees with unskilled or semi-skilled occupations 
(administrative, sales, agriculture and fisheries workers, 
blue-collar workers and labourers), and those with a net 
monthly income below 1 000€. On the contrary, individuals 
from the RA sub-sample had an education level higher than 
the primary, and consequently the majority of them earned 
a net income above 1 000€.
Ferreira LN, et al. Comparing the performance of SF-6D and EQ-5D in different patient groups, Acta Med Port 2014 Mar-Apr;27(2):236-245 
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 The COPD and the cataracts sub-samples consisted 
mainly of retired people, aged more than 60 years, married 
or living with a partner, residents in urban or semi-urban 
areas, and individuals that earned a net income above 
1 000€. These sub-samples differed in what concerns 
gender: almost half of the cataracts sub-sample were men 
whereas almost the total of the COPD sub-sample were 
men.
 Table 2 displays the frequency distributions of individual 
responses to the dimensions of the SF-6D and the EQ-5D, 
Table 1 – Characteristics of the total sample and by medical condition
Total sample
(n = 643)
Asthma
(n = 115)
COPD
(n = 72)
Cataracts
(n = 352)
RA
(n = 104)
Female (%) 58.7 70.2 2.8 56.5 92.3
Mean age (standard deviation) 64.9 (15.5) 49.2 (16.9) 68.6 (9.5) 73.0 (8.7) 51.1 (14.6)
Aged more than 60 years (%) 66.9 29.0 80.5 87.5 29.0
Married/living with a partner (%) 65.2 71.3 77.8 60.5 65.4
Primary education level (%) 49.5 46.1 51.4 56.8 26.9
Employed (%) 27.9 56.5 11.1 15.4 50.0
Residents in urban or semi-urban areas (%) 72.3 74.8 59.7 70.7 84.0
Net monthly income below 1 000€ (%) 64.7 72.3 84.7 71.0 38.4
COPD - chronic obstructive pulmonary disease; RA - rheumatoid arthritis.
Table 2 – Frequency distributions of individual responses to the dimensions of the EQ-5D and the SF-6D (%)
SF-6D
Level PF RL SF Pa MH Vi PF RL SF Pa MH Vi
Asthma COPD
1 18.3 51.3 66.1 32.2 53.9 46.1   0.0 58.3 73.6 38.9 76.4 61.1
2 27.8 31.3 14.8   7.8 33.9 29.6 25.0 36.1   9.7   5.6 18.1 23.6
3 32.2   4.3 13.0 20.0   5.2 12.2 36.1   2.8   8.3 27.8   2.8 11.1
4 14.8 13.0   4.3 25.2   6.1   8.7 29.2   2.8   5.6 19.4   2.8   1.4
5   7.0 na   1.7 14.8   0.9   3.5   5.6 na   2.8   6.9   0.0   2.8
6   0.0 na na   0.0 na na   4.2 na na   1.4 na na
Cataracts RA
1 15.9 27.3 27.3 25.0 20.5 29.5   3.8 19.2 30.8   3.8 24.0 15.4
2 35.2 46.6 20.5   9.1 46.6 40.9 38.5 34.6 15.4 11.5 48.0 34.6
3 28.4 10.2 33.0 10.2 17.0 18.2 30.8 19.2 38.5 15.4 16.0 30.8
4 11.4 15.9 15.9 36.4 14.8   6.8   7.7 26.9 15.4 19.2 12.0 19.2
5   9.1 na   3.4 13.6   1.1   4.5   3.8 na   0.0 30.8   0.0   0.0
6   0.0 na na   5.7 na na 15.4 na na 19.2 na na
EQ-5D
Level Mo SC UA PD AD Mo SC UA PD AD
Asthma COPD
1 71.3 94.8 75.7 66.1 61.7 76.4 94.4 76.4 77.8 72.2
2 28.7   5.2 24.3 33.0 37.4 23.6   4.2 20.8 22.2 26.4
3   0.0   0.0   0.0   0.9   0.9   0.0   1.4   2.8   0.0   1.4
Cataracts RA
1 62.5 89.8 62.5 30.7 38.6 46.2 65.4 38.5 15.4 23.1
2 37.5   9.1 36.4 61.3 54.6 53.8 30.8 61.5 76.9 73.1
3   0.0   1.1   1.1   8.0   6.8   0.0   3.8   0.0   7.7   3.8
Modal level is in bold; The distribution adds up to 100 by columns; Level 1 in each dimension refers to the best health state; na – not applicable; COPD - chronic obstructive pulmonary 
disease; RA - rheumatoid arthritis.
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by medical condition. Results presented in this table show 
a non-uniform frequency distribution of individual responses 
in both instruments across medical conditions.
 The results presented in table 2 show high levels of 
problems in the pain dimension, mainly in RA and cataracts 
patients with more than 50% of respondents included 
in levels 4-6 of the SF-6D. Furthermore, more than 20% 
of respondents claimed some limitations in physical 
functioning (39% of COPD patients), and thus indicating a 
possible floor effect, which is one of the weaknesses that 
characterize the SF-6D.14,35,36,40,41,43,48 It is also noteworthy 
that the role limitations and social functioning dimensions 
have non negligible percentage of individuals at the highest 
level (except in COPD in the case of role limitations) or at 
the two upper levels (in the case of social functioning). On 
the contrary, the results show that there is evidence of a 
ceiling effect in EQ-5D; that is, very few patients placed 
themselves at level 3 of the five dimensions. This result 
was expected, since (almost) all studies report that EQ-5D 
suffers from ceiling effect whatever the type of population (in 
general, healthy, suffering from specific diseases, younger, 
older, etc.).1,4,14,17,47,58 In fact, for the mobility, self-care and 
usual activities dimensions, more than 60% of asthma, 
COPD and cataracts patients responded at level 1 (no 
limitations). Moreover, in the pain/discomfort and anxiety/
depression dimensions, more than 60% of asthma and 
COPD patients responded at level 1 (no limitations), and 
about more than half of cataracts patients and more than 
three quarters of RA patients responded at level 2 (some 
limitations). Note that no more than 8% of cataracts and RA 
patients responded at level 3 (severe limitations) just in the 
pain/discomfort and anxiety/depression dimensions.
 The results of the analysis of the level of agreement 
between the descriptive systems of the dimensions of the 
instruments are shown in Table 3. Through an analysis of 
the correlation coefficients of similar dimensions (according 
to the definition used in Brazier et al35 and in Grieve et 
al),54 it appears that there are moderate correlations (> 0.5) 
among the following dimensions: 
- Asthma: pain/discomfort and pain; pain/discomfort and 
vitality; usual activities and vitality;
- COPD: there are no correlations > 0.5;
- Cataracts: pain/discomfort and pain; anxiety/depression 
and mental health; usual activities and social functioning; 
anxiety/depression and vitality; pain/discomfort and vitality;
- RA: pain/discomfort and pain; anxiety/depression and 
role limitations; mobility and physical functioning; pain/
discomfort and role limitations; usual activities and vitality.
 It should also be noted that despite the vitality dimension 
in the SF-6D not having a similar dimension explicitly 
included in the EQ-5D, it presents a moderate correlation 
with pain/discomfort, anxiety/depression and usual activities 
dimensions of the EQ-5D. In any event, all the correlations 
are far from being perfect, which can be interpreted as 
different discriminatory capacities in both instruments, due 
to the fact that variations from a given level in the dimensions 
of the SF-6D may not be fully captured by variations in the 
dimensions of EQ-5D. These results are in line with other 
studies in the literature.35,40,54
 Table 4 presents statistics of the SF-6D and EQ-5D 
indexes by medical condition and socio-demographic 
groups. 
 An analysis of the first two columns of Table 4 shows that 
both indexes have similar and good discriminative power 
by medical condition, by level of problems indicated by 
individuals and by socio-demographic group. In fact, there 
were statistically significant differences between classes in 
each group, with the exception of age classes. These results 
Table 3 – Spearman’s correlation coefficients between SF-6D and EQ-5D dimensions 
SF-6D
EQ-5D
PF RL SF Pa MH Vi PF RL SF Pa MH Vi
Asthma COPD
Mo 0.413 0.245 0.412 0.219  0.210 0.305  0.334 0.245 0.207 -0.017 -0.018  0.355
SC 0.222 0.068 0.391 0.103 -0.038 0.069  0.226 0.143 0.197  0.060 -0.002  0.226
UA 0.364 0.381 0.303 0.362  0.328 0.501  0.361 0.358 0.154  0.211  0.223  0.364
PD 0.359 0.352 0.236 0.570  0.291 0.568  0.156 0.152 0.139  0.287  0.111  0.240
AD 0.269 0.294 0.229 0.302  0.461 0.491 -0.098 0.087 0.050  0.222  0.081 -0.006
Cataracts RA
Mo 0.497 0.412 0.459 0.421  0.431 0.467  0.544 0.182 0.389  0.195  0.012  0.054
SC 0.281 0.241 0.383 0.297  0.427 0.286  0.109 0.139 0.136 -0.013  0.043 -0.028
UA 0.498 0.445 0.617 0.424  0.379 0.403  0.436 0.164 0.354  0.227  0.194  0.522
PD 0.403 0.308 0.369 0.770  0.520 0.521  0.458 0.526 0.430  0.722  0.179  0.364
AD 0.412 0.406 0.442 0.426  0.693 0.588  0.113 0.570 0.438  0.225  0.375  0.054
Correlations between similar dimensions are underlined. The five most correlated dimensions are in bold. COPD - chronic obstructive pulmonary disease; RA - rheumatoid arthritis.
Ferreira LN, et al. Comparing the performance of SF-6D and EQ-5D in different patient groups, Acta Med Port 2014 Mar-Apr;27(2):236-245 
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Table 4 – Statistics of the SF-6D and EQ-5D indexes by medical condition and socio-demographic groups
Mean (standard 
deviation) Median Median Range
Ceiling effect 
(%)
Pearson’s r 
coefficient ICC
SF-6D EQ-5D
differences a
(SF-6D - 
EQ-5D)
SF-6D EQ-5D SF-6D EQ-5D SF-6D EQ-5D
Medical condition
   Asthma 0.79 (0.14) 0.84(0.17)      -0.05*** 0.80 0.85 0.45 to 1.00 -0.02 to 1.00    8.7 40.0 0.65*** 0.64***
   COPD 0.81 (0.12) 0.86 (0.17)     -0.02** 0.83 0.85 0.57 to 0.97  0.26 to 1.00    0.0 43.1 0.40*** 0.37***
   Cataracts 0.70 (0.16) 0.69 (0.27)     -0.05** 0.68 0.73 0.39 to 1.00 -0.18 to 1.00    4.5 19.3 0.64*** 0.56***
   RA 0.63 (0.11) 0.61 (0.24)  -0.02 0.64 0.66 0.36 to 0.85 -0.18 to 1.00    0.0   3.8 0.78*** 0.60***
   pb p < 0.001 p < 0.001
N3
   N3 = 0 0.74 (015) 0.79 (0.15)      -0.04*** 0.71 0.75 0.39 to 1.00  0.52 to 1.00    4.5 25.6 0.74*** 0.74***
   N3 = 1 0.56 (0.11) 0.09 (0.17)       0.46*** 0.58 0.12 0.36 to 0.90 -0.18 to 0.37    0.0   0.0 0.61*** 0.54***
   pc p < 0.001 p < 0.001
Gender
   Female 0.67 (0.14) 0.64 (0.28)  -0.03 0.66 0.69 0.36 to 1.00 -0.18 to 1.00    1.1 11.7 0.63*** 0.51***
   Male 0.79 (0.14) 0.83 (0.16)      -0.07*** 0.78 0.85 0.49 to 1.00  0.26 to 1.00    8.3 39.2 0.71*** 0.71***
   pc p < 0.001 p < 0.001
Age (years)
   < 40 0.76 (0.15) 0.78 (0.18)   0.00 0.73 0.73 0.56 to 1.00  0.14 to 1.00 10.3 27.9 0.77*** 0.76***
   41 - 60 0.72 (0.16) 0.73 (0.27)     -0.11** 0.69 0.80 0.36 to 1.00 -0.18 to 1.00    0.7 26.6 0.80*** 0.71***
   + 60 0.71(015) 0.71 (0.26)      -0.05*** 0.68 0.73 0.39 to 1.00 -0.18 to 1.00    4.3 21.3 0.63*** 0.54***
   pb p = 0.145 p = 0.088
Education level
   Illiterate 0.68 (0.15) 0.66 (0.31)  -0.06 0.67 0.73 0.42 to 1.00 -0.18 to 1.00    0.9 19.4 0.63*** 0.50***
   Primary 0.72 (0.15) 0.73 (0.23)     -0.05** 0.68 0.73 0.37 to 1.00 -0.02 to 1.00    4.1 21.4 0.66*** 0.60***
   Lower      
   Secondary 0.76 (0.16) 0.73 (0.26)  -0.04 0.70 0.74 0.45 to 1.00  0.12 to 1.00    9.3 27.9 0.72*** 0.64***
   Upper  
   Secondary 0.78 (0.14) 0.78 (0.25)     -0.03** 0.78 0.81 0.52 to 1.00 -0.18 to 1.00    1.9 29.7 0.67*** 0.57***
   Tertiary 0.68 (0.17) 0.70 (0.27)     -0.06** 0.63 0.69 0.36 to 1.00 -0.18 to 1.00    9.5 23.8 0.83*** 0.74***
   pb p < 0.001 p < 0.001
aaccording to related-samples Wilcoxon signed-rank tests; baccording to Kruskal-Wallis H tests; caccording to Mann-Whitney U tests. COPD - chronic obstructive pulmonary disease; 
RA - rheumatoid arthritis; ICC – intraclass correlation coefficient. ***p < 0.001; **p < 0.01; *p < 0.05.
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are similar to those found in other studies. Kontodimopoulos 
et al,39 for instance, reported a good discriminative ability of 
the EQ-5D and the SF-6D by socio-demographic groups in 
individuals with different levels of health. In a similar way, 
Barton et al32 concluded that both instruments have a good 
discriminative capacity between individuals who did or 
did not follow a particular medical prescription, while Fisk 
et al,53 Marra et al43 and Barton et al52 showed that both 
the EQ-5D and SF-6D have good discriminative power 
regarding the severity of multiple sclerosis, RA and pain in 
the knees, respectively. It should, however, be noted that 
although Cunillera et al58 concluded that both the EQ-5D 
and SF-6D show a good discriminative power by socio-
demographic group and health state, the SF-6D showed 
less discriminative power as regards chronic physical 
conditions. Quercioli et al47 also found that both instruments 
have similar and good capacity of discrimination by gender, 
by chronic diseases and by factors related to lifestyle. In 
addition, they found that just the EQ-5D detect some health 
differences between age groups. 
 When comparing the EQ-5D index with the SF-6D index, 
few statistically insignificant differences were found in terms 
of age and educational background, as shown in the third 
column of Table 4. However, differences were revealed in 
terms of gender, asthma, cataracts and COPD, as well as in 
the group in which individuals suffer from a serious problem 
(N3 = 1) and in the group in which this does not occur. Similar 
results have been obtained by other researchers.33,39,57 In 
fact, it is noteworthy that it is in the group where N3 = 1 that 
there is the greatest difference between the SF-6D and the 
EQ-5D. In addition, it can be verified by the order statistics 
results (fourth to seventh columns of Table 4) that only in 
this group is the median of the SF-6D higher than that of 
the EQ-5D, and that the minimum value of the SF-6D index 
(0.36) is approximately equal to the maximum value of the 
EQ-5D index (0.37). These results may be due to the fact 
(which is often discussed in the literature) that the SF-6D 
shows less discriminative power than the EQ-5D in respect 
to more serious health problems, and therefore tends to 
show higher values than the EQ-5D.39,58
 The last two columns of Table 4 allow us to observe 
that the level of correlation between the instruments is 
moderate/strong and statistically significant in all classes 
in all of the groups considered. However, the level of 
correlation varies according to different medical condition 
and socio-demographic group. The Bland-Altman plots 
(Fig. 1) also indicate a strong agreement between the two 
instruments. Indeed, it is possible to observe that very few 
points are beyond the limits of agreement (asthma = 5.2%; 
COPD = 4.2%; cataracts = 6.8%; AR = 8.0%). It is important 
to note that these results are consistent with those of other 
studies,32,35,39,40,55 but there are studies which report a poorer 
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Figure 1 – Bland-Altman plots by medical condition 
COPD - chronic obstructive pulmonary disease; RA - rheumatoid arthritis; UAL – upper agreement limit; LAL – lower agreement limit. Vertical axis (y-axis): Difference between SF-6D 
and EQ-5D indexes; Horizontal axis (x-axis): Mean of SF-6D and EQ-5D indexes
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level of agreement. For example, the agreement between 
these two measures in populations suffering from specific 
diseases was higher than that observed in a population 
suffering from other disieases35 and in a population not 
affected by specific diseases.47
 Finally, the eighth and ninth columns of Table 4 
present the ceiling effect by medical condition and socio-
demographic groups. The ceiling effect differs considerably 
among the groups defined by medical condition and 
gender in both indexes, a finding also observed in other 
studies.58 However, some uniformity of the ceiling effect 
in different age groups and levels of education in the EQ-
5D index can be observed. However, this is not the case 
for the SF-6D index. It can also be noted that the ceiling 
effect is more pronounced in the EQ-5D index for all the 
groups analyzed, as has been observed in most studies 
using this instrument.34,45,58 One explanation for this could 
lie in the descriptive system of the EQ-5D, since it has 
fewer dimensions and fewer levels than the SF-6D and 
consequently the ceiling effect is accentuated.54,62 On the 
other hand, the time-period to which the instruments relate 
(the EQ-5D refers to the state of health ‘today’ and the SF-
6D ‘in the last four weeks’) may also contribute to this result, 
since a longer period can allow respondents to include small 
effects and slight changes in their health state that might not 
be captured by the EQ-5D (Fig. 1).63
CONCLUSION
 The use of the EQ-5D and the SF-6D in cost-utility 
analyses has been growing in recent years. The choice of 
which instrument to use can have important consequences 
and may lead to different results. For this reason, some 
researchers have focused their attention on the comparison 
of these two instruments. In this paper, our intention has 
been to make a further contribution to the study of this 
problem. We compared and analyzed the performance of 
the EQ-5D and the SF-6D (derived from the SF-36) in four 
patient groups.
 Throughout the paper, similar analyses to those carried 
out by other researchers in studies comparing the measures 
of utilities have been presented.32,35,39,47 This approach is 
justified by the implications that different utility measures 
may have for cost-utility analyses, which means that there 
is a need to further contribute to the body of evidence 
that, in this area, is obtained from a series of convergent 
experiments rather than by a single experiment.
 One of the limitations of our study is due to the 
remarkable characteristics of the samples since they may 
limit the generalizability of these results for each patient 
group. However, the main characteristics of each sub-
sample are related to the type of individuals included in 
the study. For instance, RA is a disease that traditionally 
affects more women than men, and COPD is the opposite; 
cataracts occur more frequently in elderly individuals. On 
the other hand, this limitation may only put in question the 
main conclusion of the paper – that EQ-5D and the SF-6D 
generate different utility values and that care must be taken 
on choosing the instrument to use in cost-utility analysis 
since they may generate different results – if we were trying 
to prove the contrary of this. In fact, we advocate that this 
does not constitute a real drawback of the study given that it 
is sufficient to show in a particular case that the instruments 
generate different results to prove that that they are not the 
same in all cases.
 From the results, we were able to confirm the hypothesis 
that the SF-6D and the EQ-5D showed different behaviour in 
each of the medical conditions analysed, since we observed 
that the descriptive statistics differ between instruments and 
the level of correlation is not uniform. Overall, the results 
demonstrate that the EQ-5D and the SF-6D generate different 
utility values, but there is a strong agreement between both 
indexes. Thus, the two instruments are not interchangeable 
and their results cannot be directly comparable, as has been 
argued elsewhere.32,42,47 The gap between the utility scores 
obtained by these measures may be due to, at least, two 
reasons that may occur simultaneously. The first one is the 
existent difference between the descriptive systems of both 
measures. The dimensions are different and, even when 
the concepts are close, they measure different aspects. 
The other reason is that the differences seem to be higher 
for more severe diseases. So, apart from the descriptive 
systems, it seems more probable to obtain closer utility 
values from both instruments whenever the severity and 
the burden of illness are nearer, regardless of the diseases. 
In fact, in our samples of patients with asthma, COPD, 
cataracts and RA, we cannot assure that the distributions 
of the (relative) severities within each disease are similar. 
Therefore, a possible match between the two measures 
may never be linear; it has to be conditional upon the impact 
that a health status has on the patients’ life. 
 Nevertheless, in an intrinsically subjective area as 
the measurement of quality of life we are not dealing with 
exact or true measures and scores, rather with different 
approaches to measure the same phenomenon or the 
same situation. 
 A last question may also be raised: if we already expect 
that different instruments may lead to different scores when 
measuring the same health status, why not to accept that 
they also give different scores when the severity of the 
disease and the intensity of the impact in patients’ lives is 
also different?
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